The problem of persistent platelet activation in acute coronary syndromes and following percutaneous coronary intervention
Department of Pediatrics
Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Humans; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyridines; Thrombosis
Hematology | Oncology | Pediatrics
Platelets play a central role in the atherosclerotic inflammatory response, thrombotic vascular occlusion, microembolization, vasoconstriction, and plaque progression. Persistent platelet activation poses a serious problem among patients with acute coronary syndromes (ACS) and those who have undergone percutaneous coronary intervention (PCI), placing them at risk for ischemic events and subacute stent thrombosis. Patients undergoing PCI are at risk for further ischemic events because of procedure-related platelet activation as well as the inherent persistent platelet hyperreactivity and enhanced thrombin generation associated with ACS. Persistent platelet activation following an acute coronary event and/or PCI supports incorporating antiplatelet strategies into the standard medical management of such patients. In this clinical setting, antiplatelet therapies are capable of improving outcomes. Aspirin, thienopyridines, and glycoprotein IIb/IIIa inhibitors, the 3 major pharmacologic approaches to persistent platelet activation, target various levels of the hemostatic pathways and thrombus formation.
DOI of Published Version
Clin Cardiol. 2008 Mar;31(3 Suppl 1):I17-20. doi 10.1002/clc.20363
Braunwald E, Angiolillo DJ, Bates E, Berger PB, Bhatt D, Cannon CP, Furman MI, Gurbel PA, Michelson AD, Peterson ED, Wiviott SD. (2008). The problem of persistent platelet activation in acute coronary syndromes and following percutaneous coronary intervention. Hematology/Oncology. https://doi.org/10.1002/clc.20363. Retrieved from https://escholarship.umassmed.edu/peds_hematology/106